Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep1288 | Clinical Cases–Thyroid/Other | ECE2015

Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes of adulthood

Rapti Eleni , Mousiolis Athanasios , Grammatiki Maria , Yavropoulou Maria , Zebekakis Pantelis , Daniilidis Michail , Kotsa Kalliopi

Objective: To report a case of a patient diagnosed with latent autoimmune diabetes of adulthood (LADA) based on clinical presentation and positive glutamic acid decarboxylase antibodies (GAD-abs) that converted to antibody negative diabetes after combined treatment with sitagliptin and vitamin D.Methods: A 31-year-old male presented at the emergency room with symptoms of polyuria, polydipsia, and weight loss. Blood glucose was 300 mg/dl with mild ketonur...

ea0035n7 | (1) | ECE2014

The Nordic network for endocrine nurses (NNEN).

Forsgren Maria , Wessman Ylva , Nilsson Ann-Sofie , Warn Maria , Backlund Kristina , Guldborg Anette , Follin Cecilia

Background: Previously, the endocrine nurses in Sweden, Denmark, Norway, Finland and Iceland have not been organized. As Endocrine nursing is specialized and no education for a specialist competence in endocrinology is available there is a need for a collaboration to improve the Nordic endocrine nursing.Purpose: The purpose of the Nordic network for endocrine nurses (NNEN) is to enhance the Nordic endocrine nurse knowledge and skills, and also work for a...

ea0035p53 | Adrenal cortex | ECE2014

Clinical characteristics and follow-up of patients with adrenal incidentalomas

Fernandes Vera , Santos Maria J , Pereira Maria L , Alves Marta , Souto Selma , Marques Olinda

Background: The adrenal incidentalomas (AI), adrenal masses ≥10 mm in diameter incidentally detected, have increased their prevalence due to technological advances in imaging. The adrenalectomy is indicated in functioning adrenal tumors and in cases suspected of malignancy.Objectives: To analyze the characteristics of patients with AI and to evaluate the clinical outcome, in terms of evolution toward hypersecretion and significant growth, during fo...

ea0035p224 | Clinical case reports Pituitary/Adrenal | ECE2014

Cushing's disease in patient with primary empty sella

Kurowska Maria , Malicka Joanna , Zielinski Grzegorz , Tarach Jerzy S , Maksymowicz Maria , Denew Piotr

Introduction: The empty sella syndrome (ESS) is defined as the penetration of the subarachnoid space into intrasellar region. In ESS pituitary hormonal function is usually normal, but several, mostly subtle, hormonal abnormalities have been also reported. The coexistence of Cushing’s disease and primary empty sella is very rare.Objective: The presentation of an exceptional case of a patient with Cushing’s disease associated with primary empty s...

ea0035p225 | Clinical case reports Pituitary/Adrenal | ECE2014

Temozolomide-induced marked regression of invasive Crooke's cells corticotropinoma in patient with Cushing's disease

Kurowska Maria , Malicka Joanna , Zielinski Grzegorz , Tarach Jerzy S , Maksymowicz Maria , Denew Piotr

Introduction: Crooke’s cells are normal corticotrophs with cytoplasmic accumulation of cytokeratin filaments in response to glucocorticoids excess. Crooke’s cell corticotropinomas are the unique cause of Cushing’s disease. Nearly all of them are invasive macroadenomas, generally aggressive, refractory to conventional therapy, with high recurrence rate.Aim of the study was to present a case study of a patient with Cushing’s disease cau...

ea0035p226 | Clinical case reports Pituitary/Adrenal | ECE2014

Treatment of aggressive corticotropinoma with temozolomide and bevacizumab in patient with Nelson's syndrome

Malicka Joanna , Kurowska Maria , Zielinski Grzegorz , Tarach Jerzy S , Maksymowicz Maria , Denew Piotr

Introduction: Aggressive corticotropinomas are more invasive than other pituitary tumors. Recent reports have documented the efficacy of temozolomide alone or in combination with an anti-angiogenic agent –bevacizumab in invasive pituitary adenomas treatment.Objective: Presentation a case of 56-year-old woman initially diagnosed as Cushing’s disease and the analysis of treatment procedures with special concentration on temozolomide and bevacizum...

ea0035p537 | Endocrine tumours and neoplasia | ECE2014

Sunitinib induced hypocalcaemia during treatment of pancreatic neuroendocrine tumours

Alexandraki Krystallenia , Karnezis James , Kaltsatou Maria , Chatzellis Eleftherios , Tsoli Marina , Chrysochoou Maria , Boutzios Georgios , Kaltsas Gregory

Background: Although sunitinib, an oral multitargeted tyrosine kinase inhibitor of RET, VEGFR, PDGFR, c-KIT used for cancer treatment, has a reported prevalence of hypocalcemia of 35%, this has not been documented in pancreatic neuroendocrine tumour (pNETs).Methods: We present three, out of 12, patients with pNETs treated with sunitinib who developed grade 1, 2 and 4 hypocalcemia according Common Terminology Criteria for Adverse Events v3.0 (CTCAE) crite...

ea0035p608 | Endocrine tumours and neoplasia | ECE2014

Metastatic bone disease in patients with neuroendocrine tumors

Alexandraki Krystallenia , Chrysochoou Maria , Kaltsatou Maria , Chatzellis Eleftherios , Tsoli Marina , Boutzios Georgios , Thomas Dimitrios , Kaltsas Gregory

Objective: The prevalence of metastatic bone disease in patients with neuroendocrine tumours (NETs) and their response to first line treatment with biphosphonates.Methods: We studied 271 patients (141 females) with NETs: 54 gastric, nine duodenal, 102 pancreatic, 29 small intestine, 29 appendix, 14 colon, 15 lung, one thymic, 20 unknown primary and ten elsewhere. Since September 2012 all patients with NETs and bone metastases were recruited to receive 4 ...

ea0035p716 | Neuroendocrinology | ECE2014

Long-term remission and recurrence rates after transsphenoidal surgery for cushing's disease

Moreno Paloma Moreno , Fernandez Julia Silva , Exposito Maria Rosa Alhambra , Moreno Maria angeles Galvez

Objective: Transsphenoidal surgery (TSS) presents the treatment of choice for Cushing’s disease (CD), 95% microadenomas. Remission and recurrence rates vary dependent on tumor size, extension, adenoma visibility on magnetic resonance imaging, and neurosurgical expertise. Remission rates in the postoperative vary between 55 and 85%, with a recurrence of up to 25%. The aim of this study was to describe the rate of remission and recurrence of CD in our midst after TSS, and c...

ea0035p880 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Somatostatin analogue treatment of a TSH secreting adenoma presenting with accelerated bone metabolism and a pericardial effusion

Mousiolis Athanasios , Kotsa Kalliopi , Rapti Eleni , Yavropoulou Maria , Efstathiou Maria , Foroglou Nikolaos , Yovos Ioannis

Objective: To report the unusual presentation of a thyrotropinoma in a patient with: i) accelerated bone turnover, evident as osteopenia and increased serum alkaline phosphatase level, and ii) a pericardial effusion, years before diagnosis, that resolved completely following surgery and somatostatin analogue treatment.Case report: A 38-year-old man had been treated for years for presumed hypothyroidism with thyroxine supplementation based on elevated TSH...